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The aim of this study was to evaluate the effects of recombinant human erythropoietin (Epo),
testosterone (T) or a combination of them in the treatment of erectile dysfunction (ED) in
hemodialysis patients, as well as the efficacy of sildenafil in patients unresponsive to combination
treatment. A total of 23 patients with ED were divided into two groups. The international index
of erectile function (IIEF) was used to evaluate ED and treatment response. Patients received Epo
or T treatments for 12 weeks. Later on both groups received combination treatment for another 12
weeks. Although IIEF scores increased significantly in both groups after the combination treatment,
the score changes were similar. After combination treatment, 16 patients still having IIEF scoreo26
were given sildenafil treatment in combination with Epo while T was discontinued. Although the
IIEF scores increased significantly in all patients (17.4%), only eight of them attained an IIEF score
ofX26. The baseline IIEF scores of the patients with satisfactory response to the sildenafil treatment
were higher than those with unsatisfactory response. The patients with a score of X22 responded
better to the treatment. Although Epo and/or T therapies could partially improve ED in male
dialysis patients besides correcting renal anemia and hypogonadism, sildenafil treatment could
improve ED in unresponsive patients. Especially, those with higher baseline IIEF scores benefited
more.
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Introduction
Sexual dysfunction is a frequent disorder in men
with end-stage renal disease (ESRD).1 Erectile
dysfunction (ED) is the persistent inability to
achieve or maintain an erection sufficient for
satisfactory sexual activity.2 ED is the most common
disorder of sexual dysfunction in dialysis and
predialysis patients that impairs the quality of life
of such patients, with a varying range reported upto
82% among dialysis patients.3–8 The pathogenesis
of ED includes physiological, psychological and
organic causes. Hormonal disturbances, zinc defi-
ciency, medications, peripheral neuropathy, bio-
chemical imbalances from dialysis, autonomic
insufficiency and peripheral vascular pathologies
are the suggested organic components.1 The psycho-
genic component of ED seems to arise from chronic
illness and lifestyle limitations. Patients with ESRD
have chronic fatigue, anxiety and a decline in self-
esteem, which results in decreased sexual interest.
Previously, several methods, for example, external
vacuum devices, intracavernosal injection of
vasoactive medications and penile prosthesis, have
been recommended for treating ED in patients with
ESRD.9,10 However, most patients rejected or were
dissatisfied with these methods and therefore dis-
continued them. For the patients with ESRD
together with ED, the traditional treatment consisted
of correction of anemia by recombinant human
erythropoietin (Epo), optimization of dialysis,
removal of the implicated medication and adminis-
tration of testosterone (T).1,6,9,11 Recently, sildenafil,
a selective inhibitor of phosphodiesterase type-5,
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of Nephrology, Uludağ University Medical School, Goru-
kle, Bursa 16059, Turkey.
E-mail: alpersoy@uludag.edu.tr
International Journal of Impotence Research (2006) 18, 61–68
& 2006 Nature Publishing Group All rights reserved 0955-9930/06 $30.00
www.nature.com/ijir
which is the predominant isozyme inactivating
cyclic guanosine monophosphate in the corpus
cavernosum, has been shown to be an effective,
well tolerated treatment for nonuremic men with
ED.12 Its use results in increased smooth muscle
relaxation and improved erection when nitric oxide
is released in the presence of sexual stimulation.
Several studies have indicated that sildenafil is a
well-tolerated and effective treatment for ED in men
receiving maintenance hemodialysis (HD).7,13–15
However, no study specifically addressed the com-
parison of efficacy and safety of Epo, T, combination
of both drugs and sildenafil together with Epo on
ED in the same patient population with ESRD.
We aimed to evaluate the effects of Epo, T and
combination of both drugs in treatment of ED in HD
patients with ESRD and the efficacy of sildenafil




The study was carried out between June 1999 and
May 2000. Stable male subjects older than 18 years
receiving routine outpatient HD therapy were
recruited for participation in this study. A total of
94 male patients were evaluated by a detailed
medical and sexual history, a systemic and urologic
physical examination, psychological profile and
electrocardiogram and echocardiography, if required
for cardiac evaluation. Patients with congestive
heart failure, acute ischemic heart disease or recent
(r6 months) history of cardiovascular disease,
stroke or myocardial infarction, concomitant treat-
ment with nitrates, presence of hypotension or
hypertension, penile anatomical defects and hema-
tological and/or hepatic diseases were excluded.
A total of 30 patients, each having regular partners
and a hematocrit (Hct) less than 30%, matched the
inclusion criteria. A total of 23 HD patients with ED
(International Index of Erectile Function (IIEF) score
o26 and normal penile erection response with
intracavernosal papaverine, having primary or sec-
ondary hypogonadism) were included in the study.
The study was carried out in accordance with the
guidelines of the Helsinki Declaration of Human
Studies. An informed written consent was taken
from all patients before study entry.
Study design
The multi-tier treatment study consisted of three
periods. In the first period, the patients were
divided into two groups based on age and time on
dialysis. The first group of patients were given Epo
treatment (subcutaneously, at a dose of 50 U/kg three
times per week after each dialysis session) (Epo
group, n:12) and the second group received T
treatment (intramuscular T ester compounds once
every 15 days—Sustanons 250 mg; 30 mg T propio-
nate, 60 mg T phenpropionate, 60 mg T isocaproate
and T decoanate, Organon) (T group, n:11) for 12
weeks.
In the second period, both groups had received
Epo and T combination treatment for 12 weeks
(Combination group). In the third period, patients
having IIEF score still o26, totally 16, had been
given sildenafil treatment (Viagras; Pfizer Inc.) for
12 weeks in combination with Epo by discontinuing
T (Sildenafil group). Patients were instructed to take
1 tablet of sildenafil 1 h before sexual activity, 2–3 h
after a meal. The initial dose for all patients was
25 mg; after two subsequent failures with 25 mg they
were instructed to increase the dose to 50 and
100 mg until satisfactory erection was maintained
but not to exceed more than one tablet daily.
Patients were asked to use sildenafil on the days
after dialysis.
In all periods the erectile function response to
treatment was evaluated according to the IIEF. After
using the treatment a score of X26 was accepted as
indicating restored erectile function.
Laboratory measurements
Medical and demographic data were obtained for
each subject from the dialysis records. In the
baseline period, hemoglobin (Hb), Hct, efficacy of
dialysis (Kt/V), normalized protein catabolic rate
(nPCR), serum creatinine, albumin, iron, total iron
binding capacity, transferrin saturation (TS), ferritin,
alanine aminotransferase (ALT) and serum hormone
levels including follicle-stimulating hormone (FSH),
luteinizing hormone (LH), prolactin, total T (TT,
normal range (NR): 2.7–17 ng/ml in 20–49 years and
2.1–8 ng/ml 450 years) and free T (FT, NR: 12.4–
40 pg/ml in 20–49 years and 10.8–24.6 pg/ml450
years), dehydroepiandrosterone sulfate (DHEA-S),
androstendion (AD), sex hormone binding globulin
(SHBG) and intact parathyroid hormone (iPTH)
were measured. The hematological, biochemical
and hormonal measurements were repeated with
3-month intervals.
Primary hypogonadism was biochemically
defined as a low or low normal FT level in the
presence of elevated LH and FSH. Secondary
hypogonadism was diagnosed by a low-FT level
accompanied by a low or low normal LH or FSH.
The lack of secondary sexual characteristics com-
bined with small testicles suggested hypogonadism.
Assessment of erectile function
After pharmacological stimulation by intracaverno-
sal injection of 30–60 mg papaverine under basal
conditions, penile tumescence and rigidity were
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recorded after 15 min by measuring the length and
the circumference of the penis.
All patients filled in the IIEF form, which
included ED criteria consisting of 15 questions
(Qs).16 The IIEF has five domains: erectile function
(Q1–Q5 and Q15, total score 1–30), intercourse
satisfaction (Q6–Q8, total score 0–15), orgasmic
function (Q9–10, total score 0–10), sexual desire
(Q11–12, total score 2–10) and overall sexual
satisfaction (Q13–14, total score 2–10). The erectile
function domain consisted of 6 Qs (erection fre-
quency – Q1, erection firmness – Q2, penetration
ability – Q3, maintenance frequency – Q4, main-
tenance ability – Q5, and erection confidence –
Q15). Subjects who scored o26 in this domain were
considered to have ED. The score for each item
ranges from 0 to 5 for Qs 1–10, 0 meaning no sexual
activity/no attempt at sexual intercourse, and from 1
to 5 for Qs 11–15.
Partner assessment
Partner satisfaction was assessed by a form that
consisted of seven Qs evaluating previous 1 year
(intercourse enjoyment, intercourse satisfaction,
intercourse frequency and overall satisfaction, and
change in partners’ desire level, maintenance ability
and erection confidence). Partners whose scores
ranged from 0 to 4 were considered ‘not satisfied’
with the sexual function of their partners, while those
that ranged form 4 to 5 were considered ‘satisfied’.
Statistical analysis
The data were evaluated by SPSS v. 10.0 statistical
software for Windows. Clinical and laboratory data
were presented as mean7s.e. Statistical analysis
was performed with nonparametric Wilcoxon’s
signed rank test and Mann–Whitney U-test in intra-
and intergroup comparisons, respectively. Fischer’s
exact test was used for categorical variables. The
correlations between numerical parameters were
evaluated with the Pearson bivariate correlation
test. The ROC curve was used to determine the
threshold for predicting sildenafil treatment out-
come. P-values less than 0.05 were considered to be
significant.
Results
Two patients in the T group decided to discontinue
the therapy on their own will. The results of the
rest 21 patients were evaluated. No difference was
detected between the characteristics of the Epo and
T groups (Table 1).
Erectile function response
There was no significant difference in the baseline
IIEF scores between Epo and T groups. After the
treatment, IIEF scores were significantly increased
in both groups (Po0.05, Table 2). But, the percen-
tage changes in IIEF score of Epo and T groups were
similar (37.5 vs 14.7%, respectively). IIEF score of
one patient from each group was X26. In the
combination period, although the IIEF scores of
three patients in addition to the previous two
patients increased to X26, the changes in IIEF
scores were insignificant. In the third period
sildenafil treatment was given to a total of 16
Table 1 Characteristics of patients in all periods
1 period 2 period 3 period
Epo (n: 12) T (n: 9) EpoþT (n: 21) Epoþ sildenafil (n: 16)
Age (y) 37.573.6 38.873.1 38.172.4 41.272.6
Dialysis duration (y) 3.470.8 4.771.0 4.070.6 4.770.8
BMI (kg/m2) 23.070.9 22.171.0 22.670.6 23.470.7
SBP (mmHg) 13575.1 13176.3 13373.9 13674.6
DBP (mmHg) 8172.4 7972.9 8071.8 8372.1
Kt/V 1.0370.1 1.0270.05 1.0270.06 1.0370.07
Albumin (g/dl) 3.970.1 4.170.1 4.070.1 4.070.1
nPCR 1.170.07 1.0370.03 1.0770.04 1.0770.04
iPTH (pg/ml) 3337124 3457114 273776 333791
Primary diseases
Idiopathic 4 3 7 5
Hypertension 1 1 2 2
Glomerulonephritis 3 2 5 2
Policystic kidney D. — 2 2 2
Pyelonephritis 1 1 2 2
Diabetes mellitus 3 — 3 3
Epo: recombinant human erythropoietin; T: testosterone; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood
pressure; Kt/V: dialysis adequacy; nPCR: normalized protein catabolic rate; iPTH: intact parathyroid hormone.
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patients (76%) whose IIEF scores were o26 in
addition to Epo by discontinuing T. The IIEF scores
of patients increased significantly (17.4%, Po0.05)
(Table 2). At the end of 12 weeks, the dosage of
sildenafil was increased to 50 mg in 11 patients
(69%) and to 100 mg in two patients (13%). Eight
of them (50%) had an IIEF score X26. The ratio of
patients who responded to sildenafil treatment was
higher than those of all groups and this ratio was
only comparable with the Epo group (50 vs 8.3%,
Po0.05, Figure 1).
The baseline IIEF scores and percentage change
in IIEF scores of eight patients who had satisfactory
response after the sildenafil treatment were higher
than those with unsatisfactory response (22.370.7
vs 17.271.4, Po0.01 and 23.5 vs 11.4%, P¼ 0.05,
respectively). The ROC curve for the erectile func-
tion domain showed that patients with a score of
X22 responded better to the sildenafil treatment
with a sensitivity of 62.5% and a specificity of
100% (area under the ROC curve¼ 0.883, Figure 2).
Additionally, there was no significant difference
Table 2 Changes in body mass indexes, blood pressure, hematological parameters, erectile function domain scores and testosterone
levels of the patients before and after different treatment regimens
1 period 2 period 3 period









BMI (kg/m2) 23.070.9 23.170.9 22.171.0 23.271.0* 23.270.6 23.070.6 23.470.7 23.670.7
SBP (mmHg) 135.875.1 142.577.6 131.176.3 131.177.7 137.675.4 135.773.9 136.874.6 143.775.4
DBP (mmHg) 81.672.4 84.173.3 79.472.9 78.875.6 81.973.0 80.971.9 83.172.1 86.272.5
Hemoglobin (g/dl) 7.6570.4 8.5370.5* 8.3870.5 9.2770.4** 8.8570.3 9.470.3 9.9670.3 10.070.3
Hematocrit (%) 22.671.2 25.671.4* 24.871.7 27.871.6** 26.671.1 28.871.1 30.671.1 31.171.2
Ferritin (ng/ml) 242764 219749 233782 246782 231744 212740 194745 243766
TS (%) 15.671.9 13.871.7 28.877.2 19.673.2 16.371.8 13.671.3 13.771.2 17.872.2
Epo dosage (U/kg/w) 156.276.8 146.6713.3 126.3711.8 113.1713.4 100.1714.4 86.9715.1
Albumin (g/dl) 3.970.19 3.970.14 4.170.12 4.070.08 4.070.08 3.970.1 4.070.11 3.870.35
IIEF score 15.571.6 19.571.6* 19.171.4 21.771.6* 20.571.1 21.671.0 19.871.0 23.071.4*
TT (ng/ml) 3.670.3 3.870.3 3.070.4 5.070.7* 4.370.3 3.970.4 4.270.5 4.170.5
FT (pg/ml) 8.671.3 20.172.6* 9.772.2 23.773.8* 21.772.2 12.871.1* 12.771.3 12.071.4
Epo: recombinant human erythropoietin; T: testosterone; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood
pressure; TS: transferrin saturation; IIEF: International Index of Erectile Function; TT: total T; FT: free T. *Po0.05 and **Po0.01,













Figure 1 The comparison of ratios of patients with IIEF scores
X26 after different treatment regimens. Epo: recombinant human
















Figure 2 The ROC curve of the erectile function domain score
before sildenafil treatment for predicting the outcome of the
treatment in 16 patients (area under the ROC curve¼ 0.883,
standard error¼0.090, 95% confidence interval¼ 0.626–0.983).
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concerning age, duration of dialysis, BMI, Kt/V,
nPCR, blood pressure, albumin, hematological and
hormonal values, sildenafil and Epo dosages
between sildenafil-responsive and unresponsive
groups.
When the questions related with ED in the IIEF
form were considered, the increases in erection
frequency (Q1, 26.7%), erection firmness (Q2,
42.8%), maintenance ability (Q5, 39.3%) and erec-
tion confidence (Q15, 44.4%) were found to be
significant after the sildenafil treatment (Po0.05).
The increases in penetration ability (Q3, 15.1%) and
maintenance frequency (Q4, 16.1%) were insignif-
icant. When the other domains in the IIEF form were
considered, intercourse enjoyment (Q8, 23.5%),
desire level (Q12, 26.6%) and relationship satisfac-
tion (Q14, 30%) were significantly increased after
the sildenafil treatment (Po0.05), but not others
(Figure 3).
Hematological changes
There was no difference between Epo and T groups
concerning baseline hematological parameters. In
both Epo and T groups, Hb and Hct levels increased
significantly. The changes in the combination and
sildenafil periods were statistically insignificant.
The weekly Epo dosages did not differ (Table 2). The
changes in IIEF scores of the Epo group negatively
correlate with baseline Hb (r¼0.740) and Hct
(r¼0.7427) levels (Po0.01) but not with age,
duration of dialysis, Epo dosage, changes in Hb,
Hct, TS and ferritin. We did not determine any
parameter correlated with the changes of IIEF scores
in other treatment periods.
Hormonal changes
Nine patients in the Epo group and seven patients in
the T group had primary hypogonadism while the
others had secondary hypogonadism. There was no
difference in baseline hormone levels between Epo
and T groups. TT and FT levels in the T group
increased after the treatment, although only FT level
in Epo group significantly increased (Po0.01). In
the combination period, only FT levels significantly
decreased (Po0.01, Table 2). The changes in other
serum hormone concentrations including prolactin
were insignificant. Sildenafil treatment also did not
affect serum hormone concentrations. In all periods
baseline hormone values and percentage changes in
hormone levels with the treatments did not corre-
lated with baseline IIEF scores and percentage
changes in IIEF scores.
Partner satisfaction
Seven partners participated in the partner satisfac-
tion assessment. The response rate was 43.7%. The
intercourse satisfaction improved in four (57.6%)














Figure 3 The changes in erectile function (Q1–5, Q15), intercourse satisfaction (Q6–8), orgasmic function (Q9, and10), sexual desire
(Q11, and 12) and overall sexual satisfaction (Q13, and 14) domain questions scores in patients on sildenafil before and after the
treatment (Po0.05 for the increases in Q1, Q2, Q5, Q15, Q8, Q12 and Q14).
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Partners’ desire level increased in five (71%). Four
(57.6%) reported overall satisfactory sex life. The
sex lives of three partners (42.4%) were moderately
satisfied and one was very satisfied.
Adverse effects
All patients completed the study, except for two
patients. The BMIs in the T group increased due to
mild fluid retention in most patients (Po0.05,
Table 2). Headache was reported in three subjects
(18%) and rhinitis in one subject (6%) with
sildenafil treatment. These side effects were short
lived and did not require any treatment. No subjects
reported priapism. Blood pressures were stable
during all periods (Table 2). None of the patients
had a hypotensive episode in their dialysis sessions
during the sildenafil treatment.
Discussion
ED is one of the factors negatively influencing the
quality of life of patients on HD. ED may improve
in patients with renal failure after the initiation of
HD therapy. Procci and Martin17 reported that 23
patients started on chronic HD therapy and followed
up prospectively for 2.5 years experienced an
increase in frequency of intercourse despite stability
of nocturnal penile tumescence measures. This may
be caused by adequacy of dialysis or Epo adminis-
tration.11,18 Our study showed that Epo and/or T
therapies could partially improve sexual dysfunc-
tion in the male dialysis population even though
renal anemia and hypogonadism were corrected.
The combination treatment also did not provide an
additional benefit for ED. These approaches only
restored ED (IIEF score 425) in five patients
(23.8%), whereas sildenafil treatment improved ED
in half of the unresponsive patients.
Some studies have shown improvement in sexual
function in dialysis patients with the use of Epo and
after renal transplantation.19,20 Improved sexual
function with Epo therapy has not been confirmed
by all.11,21 Further studies have demonstrated
improved nocturnal penile tumescence22 and
increased frequency of sexual intercourse,18 while
others have suggested that Epo has direct endo-
crinological benefits, in addition to correction of
anemia. Changes in endocrine functions due to
disturbances in hypothalamic–pituitary–testicular
function such as lower FT, higher LH and FSH,
and elevated prolactin levels are well known in
patients with uremia.23 However, the role of these
disturbances on development of ED is incompletely
understood. An early study attributed improved
sexual function after Epo treatment to normalization
of elevated prolactin levels,20 but other studies have
not confirmed this19,24 and in normal subjects, the
acute administration of Epo does not interfere with
prolactin secretion.25 In contrast, Haley et al.26
showed increment in low T levels in HD patients
treated with Epo, and its acute administration in
normal young males was shown to cause testicular
steroidogenesis,27 a finding that was not confirmed
in male dialysis patients.19,20,24 Although we did
not observe any change in prolactin levels, the Epo
treatment increased FT levels similar to T treatment.
The influence of Epo on hormones affecting sexual
function in this population thus remains disputed.
In the hypogonadal man whose only complaint
is decreased libido, T may be of benefit.1,28 But,
treatment with T has usually failed to improve
libido or ED in dialysis patients.29 A recent report
showed poor effectiveness of T replacement therapy
in dialysis patients with proven hypogonadism
compared with vacuum tumescence therapy (18.5
vs 73.1%).9
Goldstein et al.12 showed that 69% of 532 men
with ED experienced successful coitus with silde-
nafil, whereas this rate was 22% in the placebo
group. There have been few studies focusing on the
use of sildenafil in a small number of HD patients,
most of which are open-labeled uncontrolled trials.
Similar to our results, these studies showed that the
administration of sildenafil 25–100 mg improved ED
at a rate of 60–80% within a duration of 3 weeks to
6 months.7,13–15,30,31 In a double-blind, randomized,
placebo-controlled study of oral sildenafil (50 mg) in
selected patients with ESRD on HD for 1 month, an
improvement was observed in 85% of 21 sildenafil
patients compared with 9.5% of 20 placebo patients
when the erectile function domain was used to
evaluate primary efficacy.32 Sildenafil use resulted
in normal erectile function scores in 35% of
sildenafil patients. After the sildenafil treatment
we observed an improvement in intercourse satis-
faction, sexual desire and overall sexual satisfaction
together with ED, but not orgasmic function.
Although only one of three diabetic patients im-
proved sexual dysfunction, we could not draw
a definite conclusion for the diabetic population.
In a recent prospective pilot study, 12 patients (eight
post-transplant and four on HD) with ED due to
hypogonadism and cavernosal insufficiency showed
a good response to intramuscular monthly injections
of 250 mg T cypionate and oral 50–100 mg sildenafil
once or twice weekly for 12 months. As a result of
this study, authors suggested that this approach
might be beneficial for those with both cavernosal
arterial insufficiency and reproductive hormone
abnormalities.33 Our finding of 50% of the men
experiencing some improvement in sexual function
can be accessible, because they were a subgroup of
the whole male dialysis population who were
complaining of impotence and had proven to have
primary or secondary hypogonadism and uremic
impotence with multifactorial nature like inter-
current vascular disease, neuropathy and endocrine
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disturbances. It has been reported that patients
not responding to sildenafil treatment had a
significantly lower penile blood flow than the
responding patients.7 Furthermore, patients with
an IIEF score of X17 responded better to sildenafil
treatment.13 In our cohort this cutoff value was
found to be 22.
In our study, low FT and high prolactin levels did
not relate to the effectiveness of sildenafil treatment.
Sildenafil treatment did not affect the hormone
levels. In a recent study, the success rate was 73%
among patients with high prolactin levels and 75%
in patients with low FT levels.31 The clinical
implications of elevated prolactin levels are not
well understood and therapy has had inconsistent
effects on libido and potency. In general, all studies
suggest good tolerability of HD patients to sildena-
fil.13–15 To limit the possibility of hypotension
among HD patients, some clinicians recommend
the use of sildenafil on nondialysis days,34 although
one small study found that sildenafil did not
promote intradialytic hypotension.35
Conclusion
Epo and/or T treatments are effective in ED of male
dialysis patients to some degree. As indicated in our
study, the higher the IIEF score the higher the
response rate after Epo treatment. T treatment might
not be preferred in this population due to fluid
retention. Oral sildenafil is an effective, reliable,
well-tolerated treatment for uremic patients with
ED, and might be the drug of first choice if there is
no contraindication. It is effective in restoring
erectile function and the ability to perform inter-
course to a degree that is satisfactory for both the
patient and his partner.
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